Detecting and Treating Lung Congestion with Kidney Failure

Area of Science:

• Nephrology
• Cardiology
• Critical Care Medicine

Background:

• Fluid overload and pulmonary edema are significant risks for patients with chronic kidney disease (CKD), especially those with kidney failure.
• Lung ultrasound (LUS) is a validated method for assessing lung water, revealing high rates of asymptomatic lung congestion in kidney failure patients.
• This congestion, weakly linked to bioimpedance measures of fluid excess, correlates with increased mortality risk.

Purpose of the Study:

• To investigate the prevalence and clinical significance of lung congestion in CKD patients.
• To evaluate the effectiveness of lung ultrasound-guided treatment strategies in managing lung congestion and cardiovascular outcomes.
• To determine if targeting asymptomatic lung congestion can improve cardiovascular prognosis in predialysis and dialysis patients.

Main Methods:

• Utilized lung ultrasound to estimate lung water and identify lung congestion.
• Conducted the Lung Water by Ultra-Sound Guided Treatment (LUST) trial, employing LUS-guided therapy.
• Performed post-hoc analysis of LUST trial data and reviewed findings from three heart failure trials.

Main Results:

• Lung ultrasound identified significant asymptomatic lung congestion in kidney failure patients.
• LUS-guided treatment effectively reduced lung congestion but did not significantly lower the primary composite endpoint in the LUST trial.
• Post-hoc analysis indicated LUS use reduced recurrent acute heart failure and cardiovascular events, consistent with heart failure trial findings.

Conclusions:

• Lung congestion is prevalent and associated with poor outcomes in CKD patients.
• While LUS-guided treatment alleviates congestion, its impact on major cardiovascular events requires further investigation.
• Establishing the role of targeting asymptomatic lung congestion is a public health priority for improving cardiovascular prognosis in CKD populations.